2025
Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom
Drummond M, Finelli C, Kristo F, Kelkar S, Corman S, Raina R, Ashaye A, Dalal M, Haase D. Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom. Journal Of Blood Medicine 2025, 16: 307-319. PMID: 40585910, PMCID: PMC12206415, DOI: 10.2147/jbm.s516558.Peer-Reviewed Original ResearchHigher-risk myelodysplastic syndromesReal-world treatment patternsTreatment patternsMyelodysplastic syndromeClinical outcomesProgression to acute myeloid leukemiaProgression-free survivalMedian patient ageMedian follow-upHigh-risk diseaseFirst-line treatmentKaplan-Meier methodAcute myeloid leukemiaHealthcare resource useFollow-up post-diagnosisIPSS-R.Partial remissionTransfusion-dependentOverall survivalPatient ageMyeloid leukemiaChart reviewClinical characteristicsAdjunctive therapyAdult patientsRole of high-dose interleukin-2 for melanoma in the age of cellular therapy
Buchbinder E, Lotze M, Margolin K, Amaria R, Sarnaik A, Seery V, Eroglu Z, Khaddour K, Warner A, Kluger H, Sznol M, Atkins M, Mcdermott D, Silk A. Role of high-dose interleukin-2 for melanoma in the age of cellular therapy. Journal For ImmunoTherapy Of Cancer 2025, 13: e011119. PMID: 40447314, PMCID: PMC12128428, DOI: 10.1136/jitc-2024-011119.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesTIL infusionInterleukin-2Cellular therapyHigh-dose bolus IL-2High-dose interleukin-2Renal cell carcinoma patientsBolus interleukin-2Cytokine-related toxicitiesExcellent organ functionIL-2 monotherapyIL-2 toxicityLife-threatening side effectsPartial tumor regressionCell carcinoma patientsInterleukin-2 dosesT cell productionTreatment of patientsNational Cancer InstituteAdvanced melanomaTumor regressionCarcinoma patientsAdjunctive therapyInpatient administrationSide effects0740 Loop Gain Predicts Residual Sleep Apnea Events Among People Using Positive Airway Pressure
Eschbach E, Kushida C, Peker Y, Xu Z, Deng A, Azarbarzin A, Wellman A, Yaggi H, Sands S, Zinchuk A. 0740 Loop Gain Predicts Residual Sleep Apnea Events Among People Using Positive Airway Pressure. Sleep 2025, 48: a321-a321. DOI: 10.1093/sleep/zsaf090.0740.Peer-Reviewed Original ResearchPositive airway pressureObstructive sleep apneaPositive airway pressure therapyBody mass indexSleep apneaBaseline AHIPAP therapyAirway pressurePharyngeal collapseIncreased riskOdds ratioPositive airway pressure devicesAssociated with increased riskCoronary artery diseaseSleep apnea eventsEpisodic airway obstructionBaseline polysomnogramRandomized controlled trialsBaseline polysomnographyHigh LGAdjunctive therapyAirway obstructionUpper airwayMass indexApneaCD1d‐iNKT Axis in Infectious Diseases: Lessons Learned From the Past
Chatterjee P, Brahma S, Cresswell P, Bandyopadhyay S. CD1d‐iNKT Axis in Infectious Diseases: Lessons Learned From the Past. Scandinavian Journal Of Immunology 2025, 101: e70024. PMID: 40243400, DOI: 10.1111/sji.70024.Peer-Reviewed Original ResearchConceptsINKT cellsLipid antigensDiverse array of cytokinesRecognition of lipid antigensEra of immunotherapyINKT cell responsesInnate-like propertiesAntigen-presenting moleculesArray of cytokinesInfectious diseasesImmunotherapeutic strategiesBridge innateT lymphocytesAdjunctive therapyIFN-gIL-13IL-4Antimicrobial treatmentArray of lipidsInfluence immune reactionsAdaptive immunityImmune responseCases of infectious diseasesImmune reactionsGlycolipid antigensCommon Cryoneurolysis Targets in Pain Management: Indications, Critical Anatomy, and Potential Complications
Sailer A, Latich I, Levey A. Common Cryoneurolysis Targets in Pain Management: Indications, Critical Anatomy, and Potential Complications. Seminars In Interventional Radiology 2025, 42: 205-212. PMID: 40376212, PMCID: PMC12077947, DOI: 10.1055/s-0045-1804492.Peer-Reviewed Original ResearchQuality of lifePain managementCombination of therapiesImprove quality of lifeIncreased healthcare costsOpioid consumptionAdjunctive therapyHealthcare costsPatient's painUncontrolled painPhysical sufferingPainPotential complicationsAnatomical considerationsCryoneurolysisAbstract PainImprove qualityPatient outcomesPatientsClinical settingPerson's abilityCritical anatomyPatient pathologyTherapyPersonsPersonalizing core decompression grafting technique for osteonecrosis of the femoral head: calculating the volume of bone resected and adjunct volume required to fill the defect
Bergemann R, Massey A, Tommasini S, Wiznia D. Personalizing core decompression grafting technique for osteonecrosis of the femoral head: calculating the volume of bone resected and adjunct volume required to fill the defect. Journal Of Orthopaedic Surgery And Research 2025, 20: 229. PMID: 40033401, PMCID: PMC11874654, DOI: 10.1186/s13018-025-05606-5.Peer-Reviewed Original ResearchConceptsAdjunctive therapyVolume of boneCore decompressionBone marrow aspirate concentrateRisk of complicationsFemoral headSynthetic bone substituteAmount of boneBone substituteAspirate concentrateExpandable reamerBone regenerationBone graftPrevent collapseDebilitating diseaseReamer systemBoneAdjunctGrafting techniqueDecompressionEfficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
Chow R, Basu A, Kaur J, Hui D, Im J, Prsic E, Boldt G, Lock M, Eng L, Ng T, Zimmermann C, Scotte F. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care In Cancer 2025, 33: 193. PMID: 39953210, PMCID: PMC11828838, DOI: 10.1007/s00520-025-09251-w.Peer-Reviewed Original ResearchConceptsChemotherapy-induced nausea and vomitingEfficacy of cannabinoidsTHC:CBDMeta-analysisPrevention of chemotherapy-induced nausea and vomitingProphylaxis of chemotherapy-induced nausea and vomitingChemotherapy-induced nausea and vomiting controlControlled trialsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsNausea and vomitingChemotherapy-induced nauseaMethodsA literature searchCochrane Central RegisterComplete responseRandomized controlled trialsNo vomitingAdjunctive therapyRescue medicationAntiemetic regimensComposite endpointSubgroup analysisCannabinoidSecondary preventionCharacterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Senna M, Taylor S, Piraccini B, Shapiro J, Somani N, Jedynak J, Ogwu S, Buchanan A, Craiglow B, Ohyama M. Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s522. DOI: 10.25251/skin.9.supp.522.Peer-Reviewed Original ResearchSeverity of Alopecia ToolLoss of responseSeverity of Alopecia Tool scoreBaricitinib 4 mgLost responseMaintenance treatmentAlopecia areataLong-term maintenance therapyYears of initial treatmentWeeks of maintenance treatmentBaseline disease characteristicsSevere alopecia areataPhase 3 trialYear of treatmentPost hoc analysisBaricitinib monotherapySevere AAMaintenance therapySALT scoreMaintained responseInitial treatmentBaseline characteristicsAdjunctive therapyTreatment responseCOVID-19 infection
2024
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
Shah V, Peters A, Umpierrez G, Sherr J, Akturk H, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs P, Lal R, Mader J, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho C, Ayers A, Tian T, Aaron R, Klonoff D. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. Journal Of Diabetes Science And Technology 2024, 19: 191-216. PMID: 39517127, PMCID: PMC11571606, DOI: 10.1177/19322968241291512.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RA therapyGLP-1RAGLP-1RAsType 1 diabetesReceptor agonistsAdjunctive therapyAbsence of randomized controlled trialsIncreasing prevalence of obesityUS Food and Drug AdministrationRisk of severe hypoglycemiaEffective adjunctive therapyPrevalence of obesityTreatment of T1DFood and Drug AdministrationRandomized controlled trialsDiabetic ketoacidosisAdjunctive treatmentMetabolic outcomesSevere hypoglycemiaAutomated insulin deliveryConsensus reportDrug AdministrationTherapyIn-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor
Restrepo-Espinosa V, Lee A, Prozora S, Patel P, Nassiri N. In-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2024, 13: 101997. PMID: 39515753, PMCID: PMC12014304, DOI: 10.1016/j.jvsv.2024.101997.Peer-Reviewed Original ResearchLow-flow vascular malformationsMTOR inhibitorsClinical successVascular malformationsSide effectsLocalized intravascular coagulopathyOral aphthous ulcersKlippel-Trenaunay syndromeLymphatic malformationsVenous malformationsRe-interventionDelayed complicationsNon-syndromicTechnical successAphthous ulcersIntravascular coagulopathyD-dimerEndovascular treatmentSystemic exposureAdjunctive therapySystemic toxicityFrequent bloodMalformationsSelf-limitingMTOR inhibitionEarly vigabatrin to augment GABAergic pathways in post-anoxic status epilepticus
Maciel C, Ahmad B, Jose Bruzzone Giraldez M, Eisenschenk S, Ramsay E, Maranchick N, Peloquin C, Hirsch L, Busl K. Early vigabatrin to augment GABAergic pathways in post-anoxic status epilepticus. Epilepsy & Behavior 2024, 160: 110082. PMID: 39393141, DOI: 10.1016/j.yebeh.2024.110082.Peer-Reviewed Original ResearchStatus epilepticusGamma-aminobutyric acidGABAergic pathwayHypoxic-ischemic brain injuryPost-cardiac arrest periodHypoxic-ischemic insultOutcomes of patientsEffective adjunctive therapyInhibition of gamma-aminobutyric acidLondon-Innsbruck ColloquiumAdjunctive therapyAcute seizuresEffective therapyPoor outcomeEpilepticusExclusion criteriaEarly inhibitionSynergistic augmentationGamma-aminobutyric acid catabolismArrest periodTherapeutic nihilismSeizuresClinal trialsAllosteric modulatorsVigabatrinCCR2+ monocytes are dispensable to resolve acute pulmonary Pseudomonas aeruginosa infections in WT and cystic fibrosis mice
Öz H, Braga C, Gudneppanavar R, Di Pietro C, Huang P, Zhang P, Krause D, Egan M, Murray T, Bruscia E. CCR2+ monocytes are dispensable to resolve acute pulmonary Pseudomonas aeruginosa infections in WT and cystic fibrosis mice. Journal Of Leukocyte Biology 2024, 117: qiae218. PMID: 39365279, PMCID: PMC11953069, DOI: 10.1093/jleuko/qiae218.Peer-Reviewed Original ResearchLung tissue damageCystic fibrosisTissue damageMonocyte recruitmentImmune responsePulmonary Pseudomonas aeruginosa infectionHyper-inflammatory immune responseCystic fibrosis micePropagate tissue damagePseudomonas aeruginosaLungs of patientsChronic neutrophilic inflammationImmunological response to infectionHost immune responseMonocyte-derived macrophagesTarget monocyte recruitmentSite of injuryResponse to infectionCFTR modulatorsPA infectionChronic inflammatory disease conditionsReduced bactericidal activityAdjunctive therapyClinical outcomesEradicate infectionTHE VALUE OF ADJUNCTIVE THERAPIES IN INDIVIDUALS WITH SEVERE OBSTRUCTIVE SLEEP APNEA TREATED WITH HYPOGLOSSAL NERVE STIMULATOR
BUNTAK V, INAYA A, ZINCHUK A. THE VALUE OF ADJUNCTIVE THERAPIES IN INDIVIDUALS WITH SEVERE OBSTRUCTIVE SLEEP APNEA TREATED WITH HYPOGLOSSAL NERVE STIMULATOR. CHEST Journal 2024, 166: a6173. DOI: 10.1016/j.chest.2024.06.3655.Peer-Reviewed Original ResearchA Rare Pediatric Mandibular Mass: Diagnosis, Treatment and Reconstruction: A Case Report
Susan S, Gorman L, Santore E, Boldikova D, Ibrahim G, Kravchenko D, Khan M, Johnson D, Mehra S, Laskin W, Eskendri J. A Rare Pediatric Mandibular Mass: Diagnosis, Treatment and Reconstruction: A Case Report. Oral Surgery Oral Medicine Oral Pathology And Oral Radiology 2024, 138: e63. DOI: 10.1016/j.oooo.2024.04.096.Peer-Reviewed Original ResearchSclerosing epithelioid fibrosarcomaFibular free flap reconstructionHigh risk of metastasisAggressive clinical courseMetastasis 9 monthsRisk of metastasisEpisodes of recurrenceFree flap reconstructionMalignant fibroblastic neoplasmExcisional surgeryClinical courseFlap reconstructionHyalinized stromaAdjunctive therapyPoor prognosisSurgical siteEpithelioid cellsTreatment planningMiddle aged adultsTreatment protocolsFibroblastic neoplasmRight mandibleHigh riskMUC4 immunoreactivityLower extremitiesPPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases
Gallucci G, Hayes C, Boyer J, Barbier O, Assis D, Ghonem N. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Cells 2024, 13: 1296. PMID: 39120326, PMCID: PMC11312002, DOI: 10.3390/cells13151296.Peer-Reviewed Original ResearchPrimary biliary cholangitisPrimary sclerosing cholangitisPeroxisome proliferator-activated receptorCholestatic liver diseaseUrsodeoxycholic acidUridine 5'-diphospho-glucuronosyltransferaseObeticholic acidBile acid metabolismAdjunctive therapyIncomplete response to UDCAProgression of primary biliary cholangitisResponse to UDCALiver diseasePeroxisome proliferator-activated receptor agonistsSecond-line treatmentMarkers of cholestasisImpairment of bile flowTherapeutic targetTreatment of cholestatic liver diseasesRetention of bile acidsAlternative treatment strategiesProgression to fibrosisProliferator-activated receptorsAcid metabolismBiliary cholangitisPreclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review
Wong S, Le G, Vasudeva S, Teopiz K, Phan L, Meshkat S, Kwan A, Rhee T, Ho R, Choi H, Cao B, Rosenblat J, McIntyre R. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review. Journal Of Affective Disorders 2024, 362: 816-827. PMID: 39019223, DOI: 10.1016/j.jad.2024.07.030.Peer-Reviewed Original ResearchMajor depressive disorderKappa-opioid receptorsKappa-opioid receptor antagonistConventional antidepressantsOpioid receptor antagonistReceptor antagonistMeasures of anhedoniaClinical trialsPhase 3 pivotal trialsEarly stages of clinical trialsMu-opioid receptorsPhase 3 studyClinically-relevant dosesStages of clinical trialsDepressive disorderSystematic reviewDepressive symptomsMu-opioidOpioid receptorsAntidepressantsAdjunctive therapyClinical efficacyAdverse eventsAticaprantResearch vistasManagement of the refractory nocturnal enuresis patient to desmopressin in a pediatric population: Desmopressin + oxybutynin vs. desmopressin + imipramine
Shain S, Gitlin J, Pantazis A, Fine R, Horowitz M, Friedman S, Zelkovic P, Dyer L, Schlussel R, Freyle J, Fang A, Sommer J, Franco I. Management of the refractory nocturnal enuresis patient to desmopressin in a pediatric population: Desmopressin + oxybutynin vs. desmopressin + imipramine. Journal Of Pediatric Urology 2024, 20: 603.e1-603.e8. PMID: 38871547, DOI: 10.1016/j.jpurol.2024.05.024.Peer-Reviewed Original ResearchVancouver Symptom ScoreInternational Children's Continence SocietyWet nightsDesmopressin treatmentCombination therapyResponse rateIntent-to-treat response rateCombination therapy of desmopressinFirst-line medical therapyEfficacy of adjunctive therapyGroup IMPComplete response rateTreated with desmopressinCohort of patientsContinence successPrescribed desmopressinEnuresis patientsMedical therapyNighttime drynessChart reviewAdjunctive therapyConclusion A combinationDesmopressinOxybutyninPediatric populationAbsence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samplesCharacteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
Guh A, Li R, Korhonen L, Winston L, Parker E, Czaja C, Johnston H, Basiliere E, Meek J, Olson D, Fridkin S, Wilson L, Perlmutter R, Holzbauer S, D’Heilly P, Phipps E, Flores K, Dumyati G, Pierce R, Ocampo V, Wilson C, Watkins J, Gerding D, McDonald L. Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences. Open Forum Infectious Diseases 2024, 11: ofae127. PMID: 38577028, PMCID: PMC10993058, DOI: 10.1093/ofid/ofae127.Peer-Reviewed Original ResearchRecurrent Clostridioides difficile infectionClostridioides difficile infectionInitial CDINitrofurantoin useMultiple recurrent Clostridioides difficile infectionsPositive testPositive C. difficile testMultiple CDI recurrencesMultivariate logistic regression analysisPrevent further recurrenceAssociated with increased riskIntervention study designProportion of patientsTime of presentationCharacteristics of patientsLogistic regression analysisClinical decision makingCDI recurrenceChronic hemodialysisAdjunctive therapyIncreased riskMultivariate analysisStudy designPatientsClinical settingRationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
Barsotti G, Luciano R, Kumar A, Meliambro K, Kakade V, Tokita J, Naik A, Fu J, Peck E, Pell J, Reghuvaran A, Tanvir E, Patel P, Zhang W, Li F, Moeckel G, Perincheri S, Cantley L, Moledina D, Wilson F, He J, Menon M. Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis. Kidney International Reports 2024, 9: 1354-1368. PMID: 38707807, PMCID: PMC11068976, DOI: 10.1016/j.ekir.2024.02.006.Peer-Reviewed Original ResearchMinimal change diseaseRandomized controlled trialsSafety of metforminDouble-blindPodocyte injuryAdjunctive therapyPlacebo-controlled randomized controlled trialsPhase III studyPhase II trialPrimary glomerular diseaseFocal segmental glomerulosclerosisEffect of metforminPhase IIPlacebo-controlledPreclinical dataNovel urineChange diseaseTissue markersRandomized trialsSegmental glomerulosclerosisGlomerular diseaseMechanistic biomarkersObservational studyFSGSInexpensive agent
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply